The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Eligibility
Sex
MALE
Min age
18 Years
Max age
115 Years
Healthy volunteers
No
Inclusion criteria:
* Diagnosis of mCRPC between 01 January 2021 and 31 December 2025.
* Male sex at index, where index is the date of initial mCRPC diagnosis.
* Age 18 years at index.
Exclusion criteria:
• None
Primary outcome measure(s)
Number of Patients by Prior Therapies — Baseline
Number of Patients by Number of Post-index Lines of Therapy (LOTs) — Up to approximately 5 years
Number of Patients by Type of Therapy at Each LOT — Up to approximately 5 years
Percentage of Patients Switching From One Type of Therapy to Another at Each LOT — Up to approximately 5 years
Time to First-line (1L) Treatment Initiation (TTTI) — Up to approximately 5 years Time from index date (mCRPC diagnosis) to the start of 1L treatment.
Time to Next Therapy (TTNT) for Each LOT — Up to approximately 5 years Time from the end of each LOT to initiation of the next LOT.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.